Stocks and Investing
Stocks and Investing
Tue, May 14, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Emily Bodnar Maintained (ACRV) at Strong Buy with Increased Target to $22 on, May 14th, 2024
Emily Bodnar of HC Wainwright & Co., Maintained "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy with Increased Target from $20 to $22 on, May 14th, 2024.
Emily has made no other calls on ACRV in the last 4 months.
There are 4 other peers that have a rating on ACRV. Out of the 4 peers that are also analyzing ACRV, 1 agrees with Emily's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Aydin Huseynov of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Monday, April 29th, 2024
These are the ratings of the 3 analyists that currently disagree with Emily
- Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $25 on, Friday, April 26th, 2024
- Joseph Catanzaro of "Piper Sandler" Maintained at Buy with Increased Target to $30 on, Thursday, April 25th, 2024
- Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Increased Target to $17 on, Thursday, April 25th, 2024
Contributing Sources